Timothy Connors Net Worth

The estimated Net Worth of Timothy Connors is at least $6.81 Million dollars as of 19 November 2018. Timothy Connors owns over 34,000 units of Prestige Consumer Healthcare Inc stock worth over $1,833,118 and over the last 14 years Timothy sold PBH stock worth over $4,978,084.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Timothy Connors PBH stock SEC Form 4 insiders trading

Timothy has made over 7 trades of the Prestige Consumer Healthcare Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Timothy sold 34,000 units of PBH stock worth $1,300,500 on 19 November 2018.

The largest trade Timothy's ever made was exercising 92,045 units of Prestige Consumer Healthcare Inc stock on 5 August 2013 worth over $936,098. On average, Timothy trades about 13,997 units every 81 days since 2010. As of 19 November 2018 Timothy still owns at least 25,775 units of Prestige Consumer Healthcare Inc stock.

You can see the complete history of Timothy Connors stock trades at the bottom of the page.

What's Timothy Connors's mailing address?

Timothy's mailing address filed with the SEC is 90 NORTH BROADWAY, , IRVINGTON, NY, 10533.

Insiders trading at Prestige Consumer Healthcare Inc

Over the last 20 years, insiders at Prestige Consumer Healthcare Inc have traded over $32,224,266 worth of Prestige Consumer Healthcare Inc stock and bought 60,410 units worth $1,162,754 . The most active insiders traders include Matthew Mannelly, James M Jenness, and Dawn M. Zier. On average, Prestige Consumer Healthcare Inc executives and independent directors trade stock every 62 days with the average trade being worth of $2,469,571. The most recent stock trade was executed by Mary Beth Fritz on 1 March 2024, trading 172 units of PBH stock currently worth $6,908.

What does Prestige Consumer Healthcare Inc do?

at prestige brands, now prestige consumer healthcare, we focus on product innovation and quality in over-the-counter healthcare products to improve the lives of our customers worldwide. you may not know who prestige consumer healthcare is, but you know and use our products: clear eyes, dentek, summer's eve, monistat, bc, goody's, dramamine, and many more. for generations, our trusted brands have helped consumers care for themselves and their loved ones. our mission is to preserve this trust by continuing to provide products stewarded with our customer needs in mind. prestige consumer healthcare is a different kind of company. we are the largest independent provider of over-the-counter healthcare products in north america yet we are nimble enough to give detailed attention to each and every one of our product offerings. we are constantly improving, creating products that match the ever-changing lifestyles and needs of people and families everywhere. prestige’s success as a company is th

Complete history of Timothy Connors stock trades at Prestige Consumer Healthcare Inc

Prestige Consumer Healthcare Inc executives and stock owners

Prestige Consumer Healthcare Inc executives and other stock owners filed with the SEC include:

• Ronald Lombardi,
  Chairman of the Board, President, Chief Executive Officer
• Ronald M. Lombardi,
  Chairman, Pres & CEO
• Christine Sacco,
  Chief Financial Officer
• William PPool,
  Senior Vice President, General Counsel and Corporate Secretary
• Adel Mekhail,
  Executive Vice President - Sales and Marketing
• Christine Sacco,
  Chief Financial Officer
• Jeffrey Zerillo,
  Senior Vice President, Operations
• Adel Mekhail,
  Exec. VP of Marketing & Sales
• William C. P'Pool,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Jeffrey Zerillo,
  Sr. VP of Operations
• Gary Costley,
  Lead Independent Director
• John Byom,
  Independent Director
• James Jenness,
  Independent Director
• Natale Ricciardi,
  Independent Director
• Sheila Hopkins,
  Independent Director
• Christopher Coughlin,
  Independent Director
• Dawn Zier,
  Independent Director
• Mary Beth Fritz,
  Sr. VP of Quality & Regulatory Affairs
• Dean Siegal,
  Director of Communications
• Philip David Terpolilli,
  Director of Investor Relations
• John F. Kelly,
  Director
• Lieven Nuyttens,
  Senior VP, Operations
• Partners Viii L Pgtcr Golde...,
  
• Paul Migaki,
  VP Strategic Planning/Canada
• Thomas Hochuli,
  Vice President, Operations
• David S Marberger,
  Chief Financial Officer
• Timothy Connors,
  Chief Marketing Officer
• John Parkinson,
  Senior VP- International
• Christopher Heye,
  See remarks
• Carl J Johnson,
  Director
• Samuel C Cowley,
  General Counsel, VP Bus. Dev.
• James E Kelly,
  Senior VP - Marketing
• Mark Pettie,
  Chairman of the Board and CEO
• Ronald B Gordon,
  Director
• Charles Schrank,
  Senior V.P. of Marketing
• Peter Anderson,
  Chief Financial Officer
• David Talbert,
  Senior Vice President, Sales
• Gerard Butler,
  Chief Sales Officer
• Co Invest Ii Lpgtcr Golder ...,
  
• Fund Viii Lpgtcr Partners V...,
  
• Jean A Boyko,
  SVP, Quality & Reg. Affairs
• John Byom,
  Director
• Eric S. Klee,
  Secretary and General Counsel
• Peter Mann,
  Chief Executive Officer
• L Dick Buell,
  Director
• Mezzanine Partners Lpgtcr P...,
  
• Frank Palantoni,
  President and COO
• Eric Millar,
  Senior V.P. of Operations
• Charles Hinkaty,
  Director
• Matthew Mannelly,
  President and CEO
• Michael Fink,
  Senior V.P. of Marketing
• Raymond Silcock,
  Director
• Paul A. Hennessey,
  Vice President, Operations
• Patrick Lonergan,
  Director
• Vincent J Hemmer,
  Director
• Mezzanine Partners Lpgtcr G...,
  
• Fund Viii/B L Pgtcr Partner...,
  
• Golder Rauner Ii Llc Gtcr,
  10% owner
• Capital Partners L Pgtcr Me...,
  
• David Donnini,
  Director
• Charles Jolly,
  Secretary & General Counsel
• Celeste A. Clark,
  Director
• James D Arecca,
  Director
• William P'pool,
  See Remarks
• Mary Beth Fritz,
  SVP Quality & Regulatory